Literature DB >> 31812706

Leukocyte profiles across the cardiovascular disease continuum: A population-based cohort study.

Hilde E Groot1, Irene V van Blokland1, Erik Lipsic1, Jacco C Karper1, Pim van der Harst2.   

Abstract

INTRODUCTION: Inflammation plays a pivotal role across all stadia of the cardiovascular disease (CVD) continuum, i.e. non-obstructive coronary artery disease (CAD), myocardial infarction (MI), and ischemic heart failure (iHF). However, inflammation across CVD continuum has not been studied yet within one population. Therefore, we mapped leukocyte profiles across the continuum within the UK Biobank.
METHODS: The UK Biobank cohort study includes >500,000 participants aged 40 to 70 years who were recruited from 22 assessment centers across the United Kingdom from 2006 to 2010. A total of 333,218 individuals with available laboratory measurements at baseline were included in this study. These consisted of controls and individuals who had progression of CVD during follow-up (i.e. who developed CAD, MI, or iHF during follow-up). We investigated whether leukocytes and subtypes of leukocytes at baseline differed among the CVD continuum. Furthermore, we studied the possible interactions between sex and CVD on leukocytes.
RESULTS: Of 333,218 individuals, 325,054 (97.5%) individuals were categorized as controls, and 8164 (2.5%) individuals had progression of CVD during follow-up. Of those 8164 individuals, 4552 (1.4%) developed CAD during follow-up, 2839 (0.9%) MI, and 773 (0.2%) in iHF. Compared to controls, mean leukocyte levels at baseline increased across the CVD continuum from 6.8·109 cells/L (SD 1.7·109 cells/L) to 7.7·109 cells/L (SD 1.9·109 cells/L) (Ptrend = 2.19·10-132) in individuals who developed iHF. This increase mainly depended on an increase in neutrophils. Furthermore, controls with leukocyte levels in the highest quartile at baseline had a 1.44 higher chance of being diagnosed with CAD during follow-up compared with individuals with leukocyte levels in lower quartiles (OR 1.44, 95% CI 1.34-1.56 P = 9.63·10-21). A similar increased change was observed for neutrophils, lymphocytes, monocytes, and eosinophils. There was a significant interaction between sex and CVD continuum on lymphocytes (P = 8.49·10-5).
CONCLUSION: Overall leukocyte count increased across the CVD continuum, which mainly depended on the increase in neutrophil count. High leukocytes in individuals not having CAD at baseline were predictive for the development of CAD during follow-up. Women had a greater increase of lymphocytes across the CVD continuum compared to men. Understanding which cells are key players in which stadium, could serve as a starting point for the identification of new potential therapeutic targets in CVD.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Cardiovascular disease continuum; Leukocyte profile; UK Biobank

Year:  2019        PMID: 31812706     DOI: 10.1016/j.yjmcc.2019.11.156

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  3 in total

1.  Preoperative neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are associated with major adverse cardiovascular and cerebrovascular events in coronary heart disease patients undergoing non-cardiac surgery.

Authors:  Jan Larmann; Jessica Handke; Anna S Scholz; Sarah Dehne; Christoph Arens; Hans-Jörg Gillmann; Florian Uhle; Johann Motsch; Markus A Weigand; Henrike Janssen
Journal:  BMC Cardiovasc Disord       Date:  2020-05-18       Impact factor: 2.298

Review 2.  The role of B cells in heart failure and implications for future immunomodulatory treatment strategies.

Authors:  Gerardo García-Rivas; Elena Cristina Castillo; Adrian M Gonzalez-Gil; José Luis Maravillas-Montero; Marion Brunck; Alejandro Torres-Quintanilla; Leticia Elizondo-Montemayor; Guillermo Torre-Amione
Journal:  ESC Heart Fail       Date:  2020-06-13

Review 3.  What Is the Role of the Inflammation in the Pathogenesis of Heart Failure?

Authors:  Elena C Castillo; Eduardo Vázquez-Garza; David Yee-Trejo; Gerardo García-Rivas; Guillermo Torre-Amione
Journal:  Curr Cardiol Rep       Date:  2020-09-10       Impact factor: 2.931

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.